H.C. Wainwright analyst Patrick Trucchio has maintained their bullish stance on ALNY stock, giving a Buy rating on April 23.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Patrick Trucchio has given his Buy rating due to a combination of factors related to Alnylam Pharma’s strategic positioning and product advancements. The approval of AMVUTTRA, with its significant mortality reduction in the pivotal Phase 3 program, positions Alnylam as a leader in the ATTR-CM treatment landscape. The drug’s quarterly dosing and Medicare Part B coverage enhance its appeal to both new patients and those progressing from existing therapies.
Furthermore, Alnylam’s pipeline, including the next-generation silencer nucresiran, promises to reinforce its market leadership with biannual dosing potential. These developments, coupled with the broader market dynamics and Alnylam’s execution capabilities, underpin Trucchio’s positive outlook on the company’s potential to deliver substantial shareholder value.
In another report released on April 23, TD Cowen also maintained a Buy rating on the stock with a $371.00 price target.
Based on the recent corporate insider activity of 75 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ALNY in relation to earlier this year.